… The objective of this work is to give an update on MKI treatment of thyroid cancer by describing
the differences in thyroid cancer and the mechanisms involved in the current treatment, …

… In this Review, we will examine the current expectation that thyroid cancer can be treated
by kinase inhibitors. Most experiences using single agents—albeit usually targeting multiple …

… thyroid cancer is based on the histological type of thyroid cells. Differentiated thyroid cancer
(DTC) and de-differentiated thyroid cancer … thyroid carcinoma (PTC), follicular thyroid …

… of HDAC inhibitors and a framework for future clinical applications of HDAC inhibitors in
patients with thyroid cancer, including histologic subtypes (eg, anaplastic and medullary thyroid …

… The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer … inhibitors—…

… Thus, targeting CSF-1/CSF-1R pathway in TAMs was shown to restore the sensitivity of
thyroid cancer cells to Paclitaxel [24]. Along similar lines, JAK/STAT inhibitors can also be …

… Everolimus is by far the most extensively studied mTOR inhibitor in thyroid cancers. In a
phase 2 clinical trial, everolimus (10 mg once daily) was evaluated in locally advanced or …

… thyroid carcinomas, we studied the effect of the specific tyrosine kinase inhibitor, STI571, on
anaplastic thyroid cancer … showed marked inhibition of cell growth after treatment with STI571…

… Thyroid cancer (TC) is the eighth most frequently diagnosed cancer worldwide with a rising
… It may be difficult to differentiate ATC from poorly differentiated thyroid cancer (PDTC), which …

… thyroid cancer; advanced medullary thyroid cancer; tyrosine kinase inhibitors in thyroid
cancer; vandetanib in thyroid cancer; … of the treatment of advanced thyroid cancers using these …